[1]Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med, 1991, 324(23): 1633-1639 [2]Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J, 1998, 17(12): 1144-1148 [3]Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics, 2000, 105(6): E78 [4]Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol, 2003, 24(2): 145-148 [5]Yang S, Song R, Zhang J, et al. Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing. Arch Dis Child, 2019, 104(3): 262-267 [6]Tan XH, Zhang XW, Wang XY, et al. A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing: a retrospective study on 5277 patients. Sci Rep, 2019, 9(1): 1722 [7]Gamez-Gonzalez LB, Hamada H, Cisneros Castolo M, et al. Vital Signs as Predictor Factors of Intravenous Immunoglobulin Resistance in Patients With Kawasaki Disease. Clin Pediatr (Phila), 2018, 57(10): 1148-1153 [8]Bar-Meir M, Kalisky I, Schwartz A, et al. Prediction of Resistance to Intravenous Immunoglobulin in Children With Kawasaki Disease. J Pediatric Infect Dis Soc, 2018, 7(1): 25-29 [9]Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr, 2008, 153(1): 117-121 [10]Jakob A, von Kries R, Horstmann J, et al. Failure to Predict High-risk Kawasaki Disease Patients in a Population-based Study Cohort in Germany. Pediatr Infect Dis J, 2018, 37(9): 850-855 [11]Arane K, Mendelsohn K, Mimouni M, et al. Japanese scoring systems to predict resistance to intravenous immunoglobulin in Kawasaki disease were unreliable for Caucasian Israeli children. Acta Paediatr, 2018, 107(12): 2179-2184 [12]Song R, Yao W, Li X. Efficacy of Four Scoring Systems in Predicting Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease in a Children's Hospital in Beijing, North China. J Pediatr, 2017, 184: 120-124 [13]Shin J, Lee H, Eun L. Verification of Current Risk Scores for Kawasaki Disease in Korean Children. J Korean Med Sci, 2017, 32(12): 1991-1996 [14]Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr, 2011, 158(5): 831-835. e833 [15]Davies S, Sutton N, Blackstock S, et al. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child, 2015, 100(4): 366-368 [16]Tang Y, Yan W, Sun L, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population. Clin Rheumatol, 2016, 35(11): 2771-2776 [17]Lin MT, Chang CH, Sun LC, et al. Risk factors and derived formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease. J Formos Med Assoc, 2016, 115(5): 350-355 [18]叶晓春, 张静. 不同评分体系对重庆地区静脉丙种球蛋白无反应川崎病预测能效评价. 中国循证儿科杂志, 2016, 11(5): 337-340 [19]McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 2017, 135(17): e927-e999 [20]JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J, 2014, 78(10): 2521-2562 [21]Dallaire F, Dahdah N. New Equations and a Critical Appraisal of Coronary Artery Z Scores in Healthy Children. J Am Soc Echocardiogr, 2011, 24(1): 60-74 [22]Sato S, Kawashima H, Kashiwagi Y, et al. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients. Int J Rheum Dis, 2013, 16(2): 168-172 [23]Kawamura Y, Takeshita S, Kanai T, et al. The combined usefulness of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in predicting intravenous immunoglobulin resistance with kawasaki disease. J Pediatr, 2016, 178: 281-284. e281 [24]Fu PP, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease. Pediatr Infect Dis J, 2013, 32(8): e319-323 [25]Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr, 2007, 166(2): 131-137 [26]Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation, 2006, 113(22): 2606-2612 [27]Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr, 2006, 149(2): 237-240 [28]肖蘭, 张静, 易伦羽, 等. 静脉注射丙种球蛋白无反应川崎病预测分析. 临床儿科杂志, 2018, 36(10): 765-771 [29]Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet, 2012, 379(9826): 1613-1620 [30]Tsai MH, Huang YC, Yen MH, et al. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. J Pediatr, 2006, 148(1): 38-43 [31]Lin MC, Fu YC, Jan SL, et al. Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study. PLoS One, 2013, 8(5): e63399 [32]Kuo HC, Hsu YW, Wu MS, et al. FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease. Mediators Inflamm, 2015: 564625 [33]Shrestha S, Wiener H, Shendre A, et al. Role of activating FcgammaR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet, 2012, 5(3): 309-316 [34]Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther, 2010, 8(2): 197-203 [35]Dominguez SR, Martin B, Heizer H, et al. Procalcitonin (PCT) and Kawasaki Disease: Does PCT Correlate With IVIG-Resistant Disease, Admission to the Intensive Care Unit, or Development of Coronary Artery Lesions? J Pediatric Infect Dis Soc, 2016, 5(3): 297-302 [36]Cho KH, Kang SJ. Clinically useful predictors of resistance to intravenous immunoglobulin and prognosis of coronary artery lesions in patients with incomplete kawasaki disease. Korean Circ J, 2014, 44(5): 328-335 [37]Masuzawa Y, Mori M, Hara T, et al. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease. Ther Apher Dial, 2015, 19(2): 171-177 |